title: [Anti-viral treatment: pro or cons type I IFN?].
authors.affiliation: Neovacs, 3-5, impasse Reille, 75014 Paris, France.
authors.forename: Piers
authors.initials: P
authors.lastname: Whitehead
authors.forename: Béatrice
authors.initials: B
authors.lastname: Drouet
authors.forename: Daniel
authors.initials: D
authors.lastname: Zagury
authors.forename: Armand
authors.initials: A
authors.lastname: Bensussan
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy; D016022:Case-Control Studies; D002908:Chronic Disease; D006801:Humans; D007113:Immunity, Innate / Q000502:physiology; D007167:Immunotherapy / Q000379:methods; D007370:Interferon Type I / Q000009:adverse effects / Q000502:physiology / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000235:genetics / Q000276:immunology / Q000628:therapy; D046228:Microarray Analysis; D059467:Transcriptome; D014777:Virus Diseases / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I